Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. (Nasdaq: TARA) announced the grant of inducement non-qualified stock options totaling 41,500 shares to two new employees.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protara Therapeutics, Inc. (Nasdaq: TARA) announced the grant of inducement non-qualified stock options totaling 41,500 shares to two new employees. The options have an exercise price of $22.45, which reflects the company's closing trading price on December 1, 2020, the grant date. Vested shares will occur over four years, with an initial 25% vesting on the one-year anniversary of each employee's start date, followed by monthly vesting. This award was approved by the Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4).
Positive
- Inducement stock options granted to new employees could enhance talent acquisition efforts.
- The exercise price aligns with the recent trading price, indicating strategic compensation planning.
Negative
- None.
Details
News Market Reaction – TARA
The recorded move for TARA in the trading session of this news was +1.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 41,500 shares of common stock to two new employees.
Each stock option has an exercise price per share equal to
The Compensation Committee of Protara’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with NASDAQ Listing Rule 5635(c)(4).
About Protara Therapeutics
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com
Company Contact:
Blaine Davis
Protara Therapeutics
Blaine.Davis@protaratx.com
646-844-0337
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.